Clinical Trial

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

Study acronym: SYMPHONY
Recruiting
View on ClinicalTrials.gov →
Summary
This study will prospectively determine the feasibility and oncological safety of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in inflammatory breast cancer patients traditionally considered ineligible for SLNB due to locally advanced cancer with skin/chest wall involvement (cT4d) and heavy nodal burden at presentation (cN1/N2). This study will also assess the identification rate of sentinel lymph-node (SLN) (using single tracer mapping) after NACT in this patient population. Finally, the study will determine the long-term outcome of such cohort.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-15; most recent amendment 2026-01-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07080944
Lead Sponsor European Institute of Oncology
Conditions Invasive Breast Carcinoma, Sentinel Lymph Node Biopsy (SLNB), Neoadjuvant Chemotherapy
Enrollment 75 participants
Start Date 2025-12-12
Primary Completion 2030-07 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-06